Janice M. Mehnert

T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028

Patrick A. Ott, Yung‐Jue Bang, Sarina A. Piha‐Paul et al. · Journal of Clinical Oncology · 2018 · 965 citations

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders

Douglas B. Johnson, Ryan J. Sullivan, Patrick A. Ott et al. · JAMA Oncology · 2015 · 653 citations

Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1–Positive Endometrial Cancer: Results From the KEYNOTE-028 Study

Patrick A. Ott, Yung‐Jue Bang, Dominique Berton-Rigaud et al. · Journal of Clinical Oncology · 2017 · 504 citations

Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study

Chiun Hsu, Se‐Hoon Lee, Samuel Ejadi et al. · Journal of Clinical Oncology · 2017 · 457 citations

Keynote-028 Study, Solid Tumors, Immunology +17

Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer

Janice M. Mehnert, Anshuman Panda, Kim M. Hirshfield et al. · Journal of Clinical Investigation · 2016 · 382 citations · Full text

Tumor Biology, Immune Activation, Dna Polymerase Epsilon +15